Filter Results:
(1,014)
Show Results For
- All HBS Web
(1,014)
- People (3)
- News (261)
- Research (632)
- Events (1)
- Multimedia (6)
- Faculty Publications (300)
Show Results For
- All HBS Web
(1,014)
- People (3)
- News (261)
- Research (632)
- Events (1)
- Multimedia (6)
- Faculty Publications (300)
- Web
Harvard Business School
IlliniCare Health in August 2017. Rashid is a pioneer in the Medicaid managed care landscape, helping to ensure there is access to quality and affordable health care to the... View Details
- 28 Nov 2011
- Research & Ideas
Rethinking the Fairness of Organ Transplants
distribution of recipients across different groups by age, race, diagnosis, and blood type. "This gives policymakers the ability to focus on what's important and relevant," he adds. "Right... View Details
- 14 Dec 2020
- Research & Ideas
What Does December's Drug-Approval Dash Mean for COVID-19 Vaccines?
aspects of the drug trial and approval process, including allowing time for potential issues to materialize. When you see an FDA emergency approval for a COVID-19 vaccine, don't interpret this as a normal... View Details
- June 2004 (Revised November 2004)
- Case
Acorda Therapeutics: Rebuilding the Spinal Cord
Acorda is an early-stage life science start-up with a promising product that is close to reaching the market (Phase III clinical trials). The company is grappling with how to expand its portfolio of molecules to make the business more sustainable. It faces classic... View Details
Keywords: Decision Making; Science-Based Business; Health Testing and Trials; Business Startups; Product Development; Biotechnology Industry
Enriquez-Cabot, Juan, Jonathan West, Marina Kolesnik, and Fiona Murray. "Acorda Therapeutics: Rebuilding the Spinal Cord." Harvard Business School Case 604-014, June 2004. (Revised November 2004.)
- 01 Feb 2002
- News
It's academic. (Not!)
business administration (DBA) in accounting and control, marketing, policy and management, or technology and operations management. Another option is a joint program with... View Details
- November 2007
- Case
Antegren: A Beacon of Hope
By: Joshua D. Margolis, Thomas J. DeLong and Terence Heymann
The CEO of Biogen Idec faces a set of difficult decisions regarding a promising drug for Multiple Sclerosis that is headed for early approval by the FDA. The first in a series focuses on operational decisions triggered by the drive for early approval. Sparks discussion... View Details
Keywords: Demand and Consumers; Leadership; Ethics; Corporate Social Responsibility and Impact; Decision Choices and Conditions; Crisis Management; Health Testing and Trials; Biotechnology Industry; Pharmaceutical Industry
Margolis, Joshua D., Thomas J. DeLong, and Terence Heymann. "Antegren: A Beacon of Hope." Harvard Business School Case 408-025, November 2007.
- May 1999 (Revised July 2000)
- Teaching Note
Reading Rehabilitation Hospital: Implementing Patient-Focused Care TN
By: Jody H. Gittell and Sandra J. Sucher
Teaching Note for (9-898-172). A rewritten version of an earlier teaching note. View Details
- 27 May 2020
- Research & Ideas
What South Korea Teaches the World About Fighting COVID
whereas South Korea has 216 cases per million. "South Korea created a vast number of testing sites, which included not only big hospitals but local clinics and public health... View Details
- 01 Mar 2016
- News
Off Script
(Thinkstock) Prescription drug spending increased by more than 13 percent in the United States in 2014, raising health insurance premiums and the ire of consumers and... View Details
- 17 Nov 2003
- Research & Ideas
The Business of Babies
Chinese babies), and international restrictions and legislation concerning adoption. High-tech measures include IVF, artificial insemination, surrogacy, gamete interfallopian transfer (GIFT) in which the... View Details
- October 2019 (Revised April 2020)
- Background Note
Note on Funding Deep Tech Startups
By: Karim Lakhani, Peter Barrett and Noubar Afeyan
This Background Note provides essential information on funding deep technologies—those technologies that were inherently capital intensive, time consuming, risky, and potentially disruptive. Both dilutive and non-dilutive sources of investment are highlighted, along... View Details
Keywords: Entrepreneurship; Energy; Venture Capital; Corporate Finance; Initial Public Offering; Investment; Health Testing and Trials; Innovation and Invention; Technological Innovation; Intellectual Property; Product Design; Product Development; Information Technology; Research and Development; Risk and Uncertainty; Technology Industry; Biotechnology Industry; United States; North America; Europe; Asia
Lakhani, Karim, Peter Barrett, and Noubar Afeyan. "Note on Funding Deep Tech Startups." Harvard Business School Background Note 620-029, October 2019. (Revised April 2020.)
- 24 Mar 2020
- Research & Ideas
These Coronavirus Heroes Show Us How Crisis Leadership Works
their companies. If ever there was a time for leaders to be authentic, this is it. They need to be humble, open, and realistic about the health care and logistical challenges... View Details
- 28 Feb 2020
- News
Filling the White Space
At Able Partners, Amanda Eilian (MBA 2006) and Lisa Blau (MBA 2003) have focused primarily on women-led wellness companies, including businesses such as Goop, Moon Juice, and Daily Harvest. Now the New... View Details
- 24 Apr 2014
- News
Finding a cure for cancer became a personal mission
Thai Lee (MBA 1985), president and CEO of SHI International, talks about how a family crisis led her to funding cancer research. (Published April 2014) View Details
- 13 Aug 2018
- Research & Ideas
Women Heart Patients Have Better Survival Odds with Women Doctors
heart attack. Of those, between 1,500 to 3,000 fewer women may have died if their doctor had been female, Laura Huang, a study co-author and Harvard Business School associate professor, said in an interview. The research mirrors bias... View Details
- September 2020
- Case
Merck: COVID-19 Vaccines
By: Willy C. Shih
COVID-19 infections were still climbing across the U.S. and many other parts of the world in September 2020, and it seemed that every time Ken Frazier, the CEO of Merck & Co. consented to an interview in recent months he always seemed to hear the same question,... View Details
Keywords: Vaccines; COVID-19 Pandemic; Health Pandemics; Health Testing and Trials; Innovation and Management; Innovation Strategy; Technological Innovation; Business Strategy; Product Launch; Pharmaceutical Industry
Shih, Willy C. "Merck: COVID-19 Vaccines." Harvard Business School Case 621-028, September 2020.
- 14 Apr 2021
- Research & Ideas
The High Cost of the Slow COVID Vaccine Rollout
dollars in value, Kominers and his co-authors reported in Market Design to Accelerate COVID-19 Vaccine Supply in the March 12 issue of Science. “The value of being able to produce vaccines at scale the minute they clear View Details
- July 2009
- Teaching Note
The Miami Project to Cure Paralysis (TN)
By: Robert Steven Kaplan, Christopher Marquis and Ben Creo
Teaching Note for [408003]. View Details
- June 2007
- Article
Efficient Kidney Exchange: Coincidence of Wants in a Structured Market
By: A. E. Roth, Tayfun Sonmez and M. Utku Unver
Patients needing kidney transplants may have donors who cannot donate to them because of blood or tissue incompatibility. Incompatible patient-donor pairs can exchange donor kidneys with other pairs only when there is a "double coincidence of wants." Developing... View Details
Keywords: Organizational Structure; Size; Emotions; Human Needs; Health Care and Treatment; Health Testing and Trials; Infrastructure; Supply Chain Management; Fairness; Performance Improvement; Health Industry
Roth, A. E., Tayfun Sonmez, and M. Utku Unver. "Efficient Kidney Exchange: Coincidence of Wants in a Structured Market." American Economic Review 97, no. 3 (June 2007): 828–851.